HIV, Anti-HCV And HBsAg in Gender Differences in HIV, Anti-HCV And HBsAg in People Who Inject Drugs A Multi-stage Systematic Review And Meta-analysis Of Global Evidence Janni Leung, Amy Peacock, Samantha Colledge, Jason Grebely, Evan B Cunningham, Matthew Hickman, Peter Vickerman, Jack Stone, Adam Trickey, Kostyantyn Dumchev, Michael Lynskey, Lindsey Hines, Paul Griffiths, Richard P Mattick, Sarah Larney*, Louisa Degenhardt* Aim Among PWID, what is the gender difference in BBVs?

Screened >55 thousand studies Included >1000 studies Methods Global multi-staged systematic review and meta-analysis Screened >55 thousand studies Included >1000 studies 104 studies reported data by gender Global multi-staged systematic review and meta-analysis Screened >55 thousand studies, 104 studies reported data by gender. Best data availability for HIV, so focus on this in this 2 minute presentation

Gender differences in HIV among PWID Relative Risks (women vs men) Map shows pooled regional results of gender differences in HIV in PWID *RR of women vs men, so red is higher RR in women, and green is lower RR in women The gender differences in HIV among PWIDs differs by location. Women PWID had higher risk of HIV in Sub Saharan Africa region, pooled RR = 2.8 (Mauritius (RR=1.58, 1.20-2.08), Nigeria (RR=5.83, 4.23-8.05) and Tanzania (RR=2.69, 2.07-3.50)) And also in South Asia region, women had higher risk than men with a pooled RR = 1.7 (India (RR=2.33, 2.19-2.47)) Australasia region women had lower risk, RR = 0.4

Conclusion Conclusion HIV infection may be more prevalent in women who inject drugs compared to their male, in some locations, which may be related to women being at greater sexual risks Our results imply that gender-sensitive harm reduction and HIV prevention services can prevent and reduce harm in marginalized population of women who inject drugs